Treg-specific Nr4a1 and Nr4a2 deficient mice have increased tumor resistance and pharmacological treatments that inhibit the expression of these NR4As in tumoral Treg cells result in improved CD8+ T cell functions and tumor control (121). This evidence concerns the gene NR4A2 and neoplasm.